Page 1

■ ■ ■ ■ VISTIN PHARMA ASA - SECOND QUARTER REPORT 2021 VISTIN PHARMA VISTIN PHARMA ASA SECOND QUARTER AND FIRST HALF 2021 RESULTS PUBLISHED 19 AUGUST 2021 HIGHLIGHTS Revenue of MNOK 67 for the quarter compared to MNOK 73 in second quarter 2020 ( -8 % ) . Record high sales volume in quarter , however revenue negatively affected by significantly stronger NOK vs EUR compared to similar quarter last year Revenue of MNOK 138 YTD in 2021 compared to MNOK 134 YTD in 2020 , a growth of 2 % EBITDA of MNOK 15.6 in second quarter 2021 compared to MNOK 20.9 in second quarter 2020 ( -26 % ) . EBITDA unfavorably affected by FX , record high international freight costs due to global constraints following Covid - 19 and significantly higher electricity prices in the quarter compared to last year YTD 2021 EBITDA of MNOK 32 versus MNOK 35 YTD in 20 , a 9 % decrease All time high production volume in the quarter adjusted for seven days planned maintenance stop in FW15 Metformin capacity expansion project ( MEP ) on track and expected to be commercially operational from Q2 2022. Approximately 50 % of the total investment of MNOK 100 paid as of end June . 1 New long term supply agreement with customer signed in August with annual volume expectations of 1000 - 1500 MT Cash balance of MNOK 60 as of 30 June and no interest - bearing debt Dividend of NOK 0.5 per share paid out in June Applications for government grants of MNOK 6 approved in 1H - will be used for productivity increase and ESG projects in coming 18 months